There was concern that examination of gastric biopsy samples alone might introduce false-positive and/or false-negative data, because HER2 intratumoral heterogeneity in GC is observed in 20–70 % of HER2-positive tumors [13, 29] and is the major cause of discrepancies between biopsy samples and surgical specimens. Here, ERBB2 is linked to gastric cancer.